IXHL
EquityIncannex Healthcare Inc.
Health Care · Drug Manufacturers - Specialty & Generic
$4.24
+4.24 (+0.00%)
Open
N/A
Day Range
$4.11 - $5.17
52W Range
$2.40 - $49.80
Volume
646K
Price History
Key Statistics
Market Cap
N/A
P/E Ratio
N/A
EPS
N/A
Dividend Yield
N/A
P/B Ratio
N/A
Payout Ratio
N/A
ROE
N/A
Debt/Equity
N/A
Insider Activity
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Nov 14, 2025 |
LATHAM JOEL Chief Executive Officer |
Other | 22,608,692 | $0.0 |
| Nov 14, 2025 |
ANASTASSOV GEORGE Director |
Other | 1,686,956 | $0.0 |
| Nov 14, 2025 |
VALENTINE TROY ROBERT Director |
Other | 11,302,608 | $0.0 |
| Nov 14, 2025 |
SWAN JOSEPH Chief Financial Officer |
Other | 869,565 | $0.0 |
| Nov 14, 2025 |
SWAN JOSEPH Director |
Other | 1,686,956 | $0.0 |
| Nov 14, 2025 |
WIDDOWS PETER Director |
Other | 1,686,956 | $0.0 |
| Oct 23, 2024 |
SWAN JOSEPH Officer |
Other | 100,476 | $0.0 |
| May 6, 2024 |
SWAN JOSEPH Chief Financial Officer |
Other | 50,793 | $0.0 |
Institutional Ownership
| Holder | Shares | % Held | Value |
|---|---|---|---|
| Mirae Asset Global ETFs Holdings Ltd. | 2,751,946 | 0.77% | $11.7M |
| Arete Wealth Advisors, LLC | 2,223,450 | 0.62% | $9.4M |
| Jane Street Group, LLC | 1,491,835 | 0.42% | $6.3M |
| Virtu Financial LLC | 753,675 | 0.21% | $3.2M |
| AdvisorShares Investments, LLC | 663,727 | 0.19% | $2.8M |
| Commonwealth Equity Services, LLC | 363,400 | 0.10% | $1.5M |
| LPL Financial LLC | 335,373 | 0.09% | $1.4M |
| Osaic Holdings Inc. | 173,090 | 0.05% | $733.9K |
| UBS Group AG | 144,745 | 0.04% | $613.7K |
| Geode Capital Management, LLC | 116,349 | 0.03% | $493.3K |
Latest News
Incannex Announces Reverse Stock Split
Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 2Q 2026
Incannex Healthcare Announces Additional Appointments to Clinical Advisory Board
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
Incannex Healthcare Announces Formation of Clinical Advisory Board for PSX-001 Program
About Incannex Healthcare Inc.
Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research and development of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that is in Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synthetic psilocybin treatment in Phase 2b clinical development for patients with generalized anxiety disorder. It is also developing IHL-675A, an oral fixed dose combination drug containing synthetic cannabidiol and hydroxychloroquine sulphate to treat rheumatoid arthritis, as well as lung inflammation, acute respiratory disease, chronic obstructive pulmonary disease, asthma, bronchitis, inflammatory bowel disease, colitis, and Crohn's disease. Incannex Healthcare Inc. is headquartered in Sydney, Australia.
www.incannex.com →Dividend Safety
Assessment based on payout ratio, debt levels, profit margins, and dividend growth track record.
Borderline
Based on 4 fundamental factors
Analysis Tools
Share
No dividend data available for IXHL
Dividend Safety
Assessment based on payout ratio, debt levels, profit margins, and dividend growth track record.
Borderline
Based on 4 fundamental factors
Loading financial data...
Revenue & Earnings
No financial statement data available for IXHL.